GFM
ALLO icon

GF Fund Management’s Allogene Therapeutics ALLO Stock Holding History

GF Fund Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Buy
6,820
+1,773
+35% +$3.89K ﹤0.01% 512
2026
Q1 		$12.3K Buy
5,047
+769
+18% +$1.54K ﹤0.01% 542
2025
Q4 		$5.86K Sell
4,278
-496
-10% -$654 ﹤0.01% 618
2025
Q3 		$5.92K Sell
4,774
-594
-11% -$708 ﹤0.01% 601
2025
Q2 		$6.07K Hold
5,368
– – ﹤0.01% 615
2025
Q1 		$7.84K Buy
5,368
+965
+22% +$1.82K ﹤0.01% 589
2024
Q4 		$9.38K Buy
+4,403
New +$10.9K ﹤0.01% 554

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GF Fund Management's ALLO Position: Q2 2026 in Review

GF Fund Management increased its Allogene Therapeutics (ALLO) stake by 35% in Q2 2026, buying an estimated $3.89K and bringing the position to 6,820 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

GF Fund Management first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • GF Fund Management held 6,820 shares of Allogene Therapeutics worth $14.2K as of Q2 2026.
  • GF Fund Management bought 1,773 Allogene Therapeutics shares in Q2 2026, an estimated $3.89K.
  • Allogene Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #512 holding.
  • GF Fund Management first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.